56 results about "Hormone release" patented technology

This invention relates to growth hormone releasing factor (GRF) derivatives. In particular, this invention relates to GRF peptide derivatives having an extended in vivo half-life, for promoting the endogenous production or release of growth hormone in humans and animals.

The invention discloses novel growth hormone releasing hormone analog peptides and an application thereof in preparing medicines for treating infertility. Experiments discover that 2D, 2E or 2F peptide has obviously high hypophysis GH releasing activity and hypophysis hormone releasing specificity. Tested by the conjugation reaction of an in-vitro GHRH dimer peptide and a hypophysis GHRH receptor, 2D, 2E and 2F dimer peptides have extremely high hypophysis receptor binding activity, wherein the 2F dimer peptide has the maximum binding activity. With the 2F peptide as the representative, infertility model treatment finds out that, compared with a normal saline group and a pure cyclophosphamide control group, in the 2F dimer peptide group, the spermatocytes and the spermatogonia in the seminiferous tubules are obviously increased, the seminiferous tubule cells are arranged in order and large in volume, the cavities of the seminiferous tubules are reduced and even disappear, and dose dependency is shown. All the facts indicate that the GHRH peptides with the 2F peptide as the representative have an obvious effect of stimulating the proliferation and the maturation of spermatogonia/oogonia, thereby promoting reproduction; and as a result, the novel growth hormone releasing hormone analog peptides can be applied to medicines for treating infertility.

The present invention pertains to compositions and methods for plasmid-mediated supplementation. The compositions and method are useful for retarding the growth of the tumor, and retarding cachexia, wasting, anemia and other effects that are commonly associated in cancer bearing animals. Overall, the embodiments of the invention can be accomplished by delivering an effective amount of a nucleic acid expression construct that encodes a GHRH or functional biological equivalent thereof into a tissue of an animal and allowing expression of the encoded. gene in the animal. For example, when such a nucleic acid sequence is delivered into the specific cells of the tissue specific constitutive expression is achieved.

The invention discloses a full-length nucleotide sequence and a mature peptide nucleotide sequence of a mink growth hormone releasing hormone cDNA gene, and encoded protein amino acid sequences thereof. The mink growth hormone releasing hormone cDNA sequence is a complete open reading frame with 321 nucleotide sequences, and 106 amino acids are encoded. The mature peptide is encoded by 132 nucleotide sequences, and 44 amino acid residues are encoded. The mink growth hormone releasing hormone cDNA can be used for promoting the growths of economic animals such as minks.

MicroRNAs (miRNAs) are short non-coding RNAs that regulate gene expression and which play important roles in many cell types, including as described herein, the pancreatic β-cell. Glucagon like peptide-1 (GLP-1), a hormone released from intestinal L-cells following meal intake, exerts pleiotropic effects on β-cell function including raising intracellular cAMP levels and now represents an important therapy for type 2 diabetes. Expression of miR-132 and miR212 is upregulated by CREB protein in response increased cAMP levels in the cell; therefore, methods for detecting and evaluating β-cell engagement by GLP-1 receptor agonists by monitoring miR-132 and miR-212 expression in a subject is described. The methods herein are particularly useful in the context of longitudinal clinical trials, such as those designed for testing the durability of any single or combination therapy in type 2 diabetes populations. Because the expression of these miRNAs is not affected by glucose, fatty acid, insulin, or β-cell function, monitoring miR-132 and miR-212 expression can be used to monitor the efficacy of any agent that effects an increase cAMP in β-cells. Such agents include for example, GLP-1, glucagon, GPR-119, and GIP receptor agonists; dipeptidyl peptidase IV (DPP IV) inhibitors; and phosphodiesterase inhibitors.

A method for controlling the maturation of sex gland of verasper and kareius features that a slow-releasing hormone for cold-water fish, which contains water, gelatin, gonad stimulating hormone or ganodotropic releasing hormone or luteinizing hormone, etc. is embedded in the artificially cultured parents of verasper and kareius.

The invention relates to the field of immunology, endocrinology and oncology and, in particular, the generation of a combined immune response to determined growth factors and hormones. A synergic effect, outlined herein, between growth regulating factors (EGF, TGF and VEGF) and hormones involved in the sexual hormones release cascade or reproduction (GnRH, LH, FSH) stimulates the anti-tumor response which is expressed as a reduction in the tumor mass and an increase in the survival time.

The invention discloses a polypeptide carrier used for improving targeting ability and transfection efficiency of a medicine/gene. The polypeptide carrier has a structure represented by a formula (I): TATp-Cys-LHRHp (I), wherein TATp is a TAT fragment of HIV, Cys is Cysteine, LHRHp is an analogue of luteinizing hormone releasing hormone LHRH. The polypeptide carrier provided by the invention carries a large amount of positive charges. The polypeptide carrier has good water-solubility and high targeting ability aiming at sexual hormone dependent tumor and liver cancer. The carrier can directlycarry negatively charged nucleic acid or medicine, and mediate the nucleic acid or medicine into cells. Also, the carrier can be used for modifying other gene or medicine carriers, such that tumor targeting abilities and transfection efficiency of the gene or medicine carriers can be improved. Therefore, a novel carrier is provided for gene/medicine delivering.

The present invention relates to process of extracting growth hormone release factor (GHRF) from pilose antler. The process includes the following steps: 1. crushing pilose antler and leaching to obtain leached liquid; 2. ultrafiltering the leached liquid and collecting the pilose antler extract of molecular weight 1-10 kDa; and 3. high efficiency liquid chromatography on the pilose antler extract and collecting component containing GHRF of pilose antler. The present invention also relates to the pilose antler extract with rich GHRF, and its application in medicine, food, cosmetics, feed, etc.

The nourishing male silk moth wine is compounded with the extractive of male and female silk moth via twice spirit soaking and once water soaking; extractive of 12 kinds of Chinese medicinal materials including ginseng, pilose antler, astragalus root, fleeceflower root, wolfberry fruit, etc. via spirit soaking and water decoction; and honey. Except testosterone, estradiol, follicle-stimulation hormone releasing hormone, hypophyseal lactating essence and progestone from silk moth, the nourishing male silk moth wine contains also 18 kinds of amino acid, polysaccharide, unsaturated fatty acid and trace elements essential for human body. The nourishing male silk moth wine has several tonic effects.

The invention mainly relates to fusion protein which is composed of a hormone releasing factor derivative produced through human promoting corpus luteum (GnRH), a lacunae body PE40 or PE38 of pseudomonad exotoxin A, and the mutant thereof which are connected in series, the invention has the key points that the 5, 7, and 8-position amino acid of the N tail end of LHRH is abruptly changed, to ensure the abruptly changed fusion protein to have the stronger tomour cell affinity and distinguishing destruction compared with the known target-oriented fusion protein.

The invention discloses a composition for dredging breast microcirculation to maintain autologous glandular cells and a preparation method thereof. The composition takes oligopeptide-1 and multiple medicinal plant extracts as main components, and can balance the ratio of in vivo estradiol to progesterone mainly by reducing hormones released by autologous gonadotropin; moreover, the composition can promote metabolism of human breast tissues, inhibit the activity of monoamine oxidase in breast tissues and synthesis of collagenous fibers, and inhibit abnormal hyperplasia of endothelial growth factors and basic fibroblast growth factors of breast blood vessels. The composition can effectively dredge breast channels and collaterals, improve breast microcirculation, discharge toxins accumulated in breasts, eliminate breast catheter hydrops and hyperemia edema, and restore the health and vitality of breasts. The composition has the effects of dredging, discharging, repairing, nourishing and strengthening mammary glands to achieve breast strengthening, beautification and protection, has the effects of preventing mammary diseases and breast healthcare, can realize 'preventive treatment of diseases', and can improve the sub-health state of breasts while preventing the diseases.

Peptide, derivatives of leutenizing hormone releasing hormone that are capable of binding radionuclides are provided. The peptide derivatives are readily labeled with isotopes of rhenium or technetium, while retaining their ability to tightly bind LHRH receptors. Methods for preparing the labeled peptides and their use in methods of radiodiagnosis and radiotherapy are described.

The invention discloses a novel fusion protein. A peptide segment (preferably a protein transduction domain (PTD)) is introduced, so as to improve the cell killing activity of an immunotoxin human leuterinizing hormone releasing hormone-Pseudomonas aeruginosa exotoxin A derivative (GnRH-PE39KDEL), and the peptide segment is positioned on the C-terminal of the human leuteinizing hormone releasing hormone (GnRH) and the N-terminal of the Pseudomonas aeruginosa exotoxin A derivative (PE39KDEL) to form the novel fusion protein together with the GnRH and PE39KDEL. The invention also relates to a nucleotide sequence for coding the fusion protein, an expression vector containing the nucleotide sequence, a host cell containing the expression vector and an application of the novel fusion protein used as an immunotoxin in an anti-cancer medicine.

The present invention relates to compositions comprising two sustained release formulations, the first being capable of releasing a gonadotropin releasing hormone composition and the second an estrogenic composition. The compositions of the invention can be employed for an improved androgen deprivation therapy of prostate cancer, in which therapy loss of bone mineral density and the occurrence and severity of hot flashes are minimized through the maintenance of a minimally adequate estrogen level.

The present invention relates to methods of making Gonadotropin Releasing Hormone ('GnRH') (also known as Leutinizing Hormone Releasing Hormone ('LHRH')) receptor antagonists.

The invention discloses salmonella choleraesuis C500 (pVAX-S/GnRH-2a/KISS1-asd) which is preserved in the China Center for Type Culture Collection and has the preservation number of CCTCC NO:M 2020055. The strain is applied to preparation of drugs or vaccines for controlling animal oestrus performance. The invention further discloses two plasmids, i.e., a pVAX-S/GnRH-asd plasmid and a pVAX-S/GnRH-2a/KISS1-asd plasmid. The two plasmids can also be applied to preparation of the drugs or the vaccines for controlling animal oestrus performance. The invention also discloses a gene vaccine for controlling animal oestrus performance and a preparation method thereof. After animals are immunized by the vaccine, antibodies of a gonadotrophin releasing hormone and KISS1 are generated, animal endogenous hormones are neutralized, aggressivity of the animals is reduced, and the problems of dysphoria, anorexia and abnormal excitation of the animals in the oestrus period are relieved.

The invention relates to a composition of a gonadotropic hormone releasing hormone analogue. A liquid chromatography-mass spectrometry technology is used for determining testosterone and the gonadotropic hormone releasing hormone analogue; furthermore, the invention provides a method for simultaneously and successfully detecting the testosterone and the gonadotropic hormone releasing hormone analogue in a sample; and after the gonadotropic hormone releasing hormone analogue and the composition thereof are used, the content and the change process of the gonadotropic hormone releasing hormone analogue and the testosterone in a body are simultaneously detected.